Answers are grounded in this paper and cite their sources.
We performed a review of the literature and compiled clinical considerations for the management of individuals with high-risk germline mutations when they develop prostate cancer. The quality of the evidence is low, and there is an immediate need for further research and the development of consensus guidelines to guide clinical practice for these individuals.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: